Generare,
a Paris-based biotechnology company focused on generating molecular data for
drug development, has raised €20 million in a Series A funding round. The round
was co-led by Alven and Daphni, with participation from existing investors
including Galion.exe, Teampact Ventures, and VIVES Partners.
Drug
discovery has historically been constrained to a relatively narrow chemical
space, largely due to limited data availability beyond it. At the same time,
microbial genomes contain a vast reservoir of molecular diversity developed
over billions of years, much of which remains unexplored. Generare is focused
on generating and characterising this previously inaccessible data at scale to
make it usable for drug development.
Founded
in 2023 by Guillaume Vandenesch and Vincent Libis, the company is building a
large-scale dataset of novel small molecules derived from microbial genomes. By
decoding previously unexplored biological data, it aims to expand the chemical
space available for drug discovery and address long-standing limitations in
access to high-quality molecular data.
The
company specialises in small molecules, the class of compounds behind many
widely used medicines, with each newly identified molecule contributing to an
expanding dataset. Its platform combines high-throughput cloning and sequencing
technologies to identify, express, and characterise bioactive compounds,
generating structured data on their properties and potential therapeutic
applications.
According
to co-founder and CEO Vandenesch, the lack of novel, high-quality molecular
data remains a key constraint in drug discovery, limiting the effectiveness of
existing approaches and models.
Generare
reports increasing adoption of its platform among pharmaceutical and research
organisations, with newly identified molecules being used in early-stage drug
development. The company is focused on scaling its dataset and expanding its
capabilities to meet growing demand.
The
funding will be used to expand the company’s compound library, scale its
discovery platform, and grow its multidisciplinary team as it continues to
develop its data-driven approach to drug discovery.